George Church and an entrepreneurial postdoc join the hunt for AAV 2.0 with a new vector-cloaking technology
About five years ago, George Church and his new postdoc, Ying Kai Chan, sat hunched over a laptop in the genetics pioneer’s Harvard office and stared in bewilderment at an old paper.
The paper documented early trials for Glybera, the first and at the time only gene therapy approved anywhere on the planet. Less than three dozen patients ever received it, but in the years before Luxturna and Zolgensma, it gave researchers an example they could point to for gene therapy actually working.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.